PTO/SB/08a (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE a Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

LWENT BI AFFEICANT

Application Number 10/650,585

Filing Date August 28, 2003

First Named Inventor Thibeault, D. et al

Art Unit To be assigned

Examiner Name To be assigned

Attorney Docket Number 13/082-1-D1

Sheet U. S. PATENT DOCUMENTS Examiner Initials Publication Date Name of Palentee or Pages, Columns, Lines, Where **Document Number** Relevant Passages or Relevant Figures Appear MM-DD-YYYY Applicant of Cited Document Number-Kind Code² (# kn บรั ับร-US-USũš-US-US-ŨŠ-ÚS-บร-UŠ-US-ŪSuš-์ บิร-US-US-์ บัร-

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ 1KInd Code ⁶ (# knawn)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	۳٥
MM		WO 01/68818	09/20/2001	ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P.		
		WO 97/08304	03/06/1997	ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P.		
	l					
	[

Examiner Signaturø	Made	ls	Date Considered	9-20-011
		, (1044

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the emount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

ENTE TRACES Substitute for form 14498/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

22

Sheet

	Complete if Known	
Application Number	10/650,585	
Filing Date	August 28, 2003	
First Named Inventor	Thibeault, D. et al	
Art Unit	To be assigned	
Examiner Name	To be assigned	
Attomey Docket Number	13/082-1-D1	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Ci		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
MM	*******	LILIANA CHEMELLO ET AL, The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C; Journal of Hepatolgy1995; Vol. 23 (suppl.2) page 8-12; issue number 0169-5185; Clinica Medica 2 and Anatonia Patologicu, University of Pudavo, Italy		
		M. WENZEL ET AL; Establishment of a Cell-based Assay for Evaluation of Compounds against HCV NS2-3 Protease Activity; Session 8.H. Paper 91; 1999 page 409; XP-001041586		
		LUISA PIERONI ET AL; In Vitro Study of the NS2-3 Protease of Hepatitis C Virus; Journal of Virology 9/1997 page 6373-6380 Vol. 71 No. 9; American Society for Microbiology		
		PAUL L. DRAKE ET AL; Inhibition of Hepatitis C Virus NS2/3 processing by NS4A peptides; The Journal of Biological Chemistry; 1999, Vol. 274 No. 49 page 34511-34514; The American Society for Biochemistry and Molecular Biology, Inc. USA		
	******************************	KAREN E. REED ET AL; Hepatitis C Virus-Encoded NS2-3 Protease: Cleavage-Site Mutagenesis and Reuirements for Bimolecular Cleavage; Journal of Virology 7/1995 Vol. 69 No. 7 page 4127-4136; American Society for Microbiology		
		ELISA SANTOLINI ET AL; The NS2 Protein of Hepatitis C Virus Is a Transmembrane Polypeptide; Journal of Virology 12/1995 Vol. 69 No. 12 page 7461-7471; American Society for Microbiology	*******	
		DIANE THIBEAULT ET AL; In Vitro Characterization of a Purified NS2/3 Protease Variant of Hepatitis C Virus; The Journal of Biological Chemistry; 12/2001, Vol. 276 No. 49 page 46678-46684; The American Society for Biochemistry and Molecular Biology, Inc		
		Copy of International Search Report for PCT/CA 01/01796		

$\overline{}$			
Examiner Signature	Molly	Date Considered	9-20-04

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.